Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramana, K. V.
Right arrow Articles by Srivastava, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramana, K. V.
Right arrow Articles by Srivastava, S. K.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 53:2910-2920, 2004
© 2004 by the American Diabetes Association, Inc.

Activation of Nulcear Factor-{kappa}B by Hyperglycemia in Vascular Smooth Muscle Cells Is Regulated by Aldose Reductase

Kota V. Ramana1, Brian Friedrich1, Sanjay Srivastava2, Aruni Bhatnagar2, and Satish K. Srivastava1

1 Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, Texas
2 Division of Cardiology, Department of Medicine, University of Louisville, Louisville, Kentucky

Activation of the polyol pathway has been linked to the development of secondary diabetic complications. However, the underlying molecular mechanisms remain unclear. To probe the contribution of this pathway, we examined whether inhibition of aldose reductase, which catalyzes the first step of the pathway, affects hyperglycemia-induced activation of the inflammatory transcription factor nuclear factor (NF)-{kappa}B. Treatment of vascular smooth muscle cells with the aldose reductase inhibitors tolrestat and sorbinil prevented high-glucose–induced protein kinase C (PKC) activation, nuclear translocation of NF-{kappa}B, phosphorylation of IKK, and the increase in the expression of intracellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and aldose reductase. High-glucose–induced NF-{kappa}B activation was also prevented by the PKC inhibitors chelerythrine and calphostin C. Ablation of aldose reductase by small interference RNA (siRNA) prevented high-glucose–induced NF-{kappa}B and AP-1 activation but did not affect the activity of SP-1 or OCT-1. Stimulation with iso-osmotic mannitol activated NF-{kappa}B and increased the expression of aldose reductase but not ICAM-1 and VCAM-1. Treatment with aldose reductase inhibitors or aldose reductase siRNA did not affect mannitol-induced NF-{kappa}B or AP-1 activation. Administration of tolrestat (15 mg · kg–1 · day–1) decreased the abundance of activated NF-{kappa}B in balloon-injured carotid arteries of diabetic rats. Collectively, these results suggest that inhibition of aldose reductase, which prevents PKC-dependent nonosmotic NF-{kappa}B activation, may be a useful approach for treating vascular inflammation caused by diabetes.

Address correspondence and reprint requests to Satish K. Srivastava, Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston, TX 77555. E-mail: ssrivast{at}utmb.edu


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.